11C-acetate PET imaging of prostate cancer.

UNLABELLED 11C-Acetate can act as a probe of tissue metabolism through entry into catabolic or anabolic metabolic pathways as mediated by acetyl-coenzyme A. The uptake of (11)C-acetate in prostate cancer was investigated to determine whether this tracer has potential in tumor identification. METHODS Twenty-two patients with prostate cancer underwent PET after intravenous administration of 740 MBq (11)C-acetate. Eighteen of the 22 patients were also investigated with (18)F-FDG PET. Standardized uptake values (SUVs) for each tumor were investigated for tracer activity at 10-20 min after (11)C-acetate and 40-60 min after (18)F-FDG administration. RESULTS Adenocarcinoma of the prostate showed variable uptake of (11)C-acetate, with SUVs ranging from 3.27 to 9.87. In contrast, SUVs for (18)F-FDG ranged from 1.97 to 6.34. By visual inspection, (11)C-acetate accumulation in primary prostate tumors was positive in all patients, whereas (18)F-FDG accumulation was positive in only 15 of 18 patients. (11)C-Acetate PET in a patient with lymph node metastasis showed high intrapelvic accumulation corresponding to metastatic sites. Similarly, 2 patients with bone metastases were (11)C-acetate avid. CONCLUSION (11)C-Acetate shows marked uptake in prostate cancer and is more sensitive in detection of prostate cancer than is (18)F-FDG PET. (11)C-Acetate represents a new tracer for detection of prostate cancer with PET, measuring radiopharmaceutical uptake pathways that are different from those measured by (18)F-FDG.

[1]  M J Welch,et al.  Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. , 2001, Nuclear medicine and biology.

[2]  N. Sadato,et al.  The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. , 1999, Japanese journal of clinical oncology.

[3]  A. Belldegrun,et al.  Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. , 1999, The Journal of urology.

[4]  A. Partin,et al.  Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients , 1999, Cancer.

[5]  N. Sadato,et al.  C-11 ACETATE PET IMAGING OF PROSTATE CANCER , 1999 .

[6]  G. Murphy,et al.  ProstaScint® scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients , 1998 .

[7]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[8]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[9]  T. A. Smith,et al.  FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.

[10]  P. Shreve,et al.  Imaging of the pancreas and related diseases with PET carbon-11-acetate. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  G Jakse,et al.  Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. , 1996, The Journal of urology.

[12]  H D Humes,et al.  Carbon-11-acetate PET imaging in renal disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  B. Långström,et al.  Synthesis of [1-11C], [2-11C], [1-11C](2H3) and [2-11C](2H3)acetate for in vivo studies of myocardium using PET. , 1994, Nuclear medicine and biology.

[14]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  R. Lufkin,et al.  Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers , 1994, Cancer.

[16]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  T Jones,et al.  Glucose utilization in vivo by human pulmonary neoplasms , 1987, Cancer.

[18]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  G Di Chiro,et al.  Prediction of survival in glioma patients by means of positron emission tomography. , 1985, Journal of neurosurgery.

[20]  T. A. Smith,et al.  Facilitative glucose transporter expression in human cancer tissue. , 1999, British journal of biomedical science.

[21]  G. Murphy,et al.  ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. , 1998, The Prostate.